Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
American Journal of Respiratory and Critical Care Medicine
|
January 11, 2020
Optimizing β-Lactams against Tuberculosis
Veronique R de Jager, Naadira Vanker, Lize van der Merwe, et al.
Antimicrobial Agents and Chemotherapy
|
May 23, 2023
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832
Rodney Dawson, Andreas H Diacon, Kim Narunsky, et al.
Antimicrobial Agents and Chemotherapy
|
May 6, 2020
Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment"
Andreas H Diacon, Veronique R De Jager, Rodney Dawson, et al.
Antimicrobial Agents and Chemotherapy
|
January 29, 2020
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
Andreas H Diacon, Veronique R De Jager, Rodney Dawson, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 21, 2025
Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and Beyond
Saskia Janssen, Caryn Upton, Veronique R de Jager, et al.
The New England Journal of Medicine
|
March 27, 2020
Telacebec (Q203), a New Antituberculosis Agent
Veronique R de Jager, Rodney Dawson, Christo van Niekerk, et al.
Annals of the American Thoracic Society
|
September 26, 2023
Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept Study
Saskia Janssen, Caryn M Upton, Veronique R De Jager, et al.
British Journal of Clinical Pharmacology
|
June 29, 2018
Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children
Elin M Svensson, Jeannine du Bois, Rene Kitshoff, et al.
The Journal of Antimicrobial Chemotherapy
|
March 28, 2025
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043
Simon E Koele, Norbert Heinrich, Veronique R De Jager, et al.
Science Translational Medicine
|
February 4, 2021
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis
Yingda L Xie, Veronique R de Jager, Ray Y Chen, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
American Journal of Respiratory and Critical Care Medicine
|
January 11, 2020
Optimizing β-Lactams against Tuberculosis
Veronique R de Jager, Naadira Vanker, Lize van der Merwe, et al.
Antimicrobial Agents and Chemotherapy
|
May 23, 2023
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832
Rodney Dawson, Andreas H Diacon, Kim Narunsky, et al.
Antimicrobial Agents and Chemotherapy
|
May 6, 2020
Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment"
Andreas H Diacon, Veronique R De Jager, Rodney Dawson, et al.
Antimicrobial Agents and Chemotherapy
|
January 29, 2020
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
Andreas H Diacon, Veronique R De Jager, Rodney Dawson, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 21, 2025
Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and Beyond
Saskia Janssen, Caryn Upton, Veronique R de Jager, et al.
The New England Journal of Medicine
|
March 27, 2020
Telacebec (Q203), a New Antituberculosis Agent
Veronique R de Jager, Rodney Dawson, Christo van Niekerk, et al.
Annals of the American Thoracic Society
|
September 26, 2023
Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept Study
Saskia Janssen, Caryn M Upton, Veronique R De Jager, et al.
British Journal of Clinical Pharmacology
|
June 29, 2018
Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children
Elin M Svensson, Jeannine du Bois, Rene Kitshoff, et al.
The Journal of Antimicrobial Chemotherapy
|
March 28, 2025
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043
Simon E Koele, Norbert Heinrich, Veronique R De Jager, et al.
Science Translational Medicine
|
February 4, 2021
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis
Yingda L Xie, Veronique R de Jager, Ray Y Chen, et al.
Page
of 1